SHP2 is required for growth of KRAS-mutant non-small-cell lung cancer in vivo

S Mainardi, A Mulero-Sánchez, A Prahallad… - Nature medicine, 2018 - nature.com
RAS mutations are frequent in human cancer, especially in pancreatic, colorectal and non-
small-cell lung cancers (NSCLCs),–. Inhibition of the RAS oncoproteins has proven difficult …
被引用次数：309 相关文章

SHP2 is required for growth of KRAS-mutant non-small-cell lung cancer in vivo

S Mainardi, A Mulero-Sanchez, A Prahallad… - Nature Medicine, 2018 - go.gale.com
RAS mutations are frequent in human cancer, especially in pancreatic, colorectal and non-
small-cell lung cancers (NSCLCs). sup. 1-3. Inhibition of the RAS oncoproteins has proven …

[引用][C] SHP2 is required for growth of KRAS-mutant non-small-cell lung cancer in vivo

S Mainardi, A Mulero-Sánchez, A Prahallad… - Nature Medicine, 2018 - cir.nii.ac.jp

SHP2 is required for growth of KRAS-mutant non-small-cell lung cancer in vivo

S Mainardi, A Mulero-Sánchez… - Nature …, 2018 - pubmed.ncbi.nlm.nih.gov
RAS mutations are frequent in human cancer, especially in pancreatic, colorectal and non-
small-cell lung cancers (NSCLCs) 1-3. Inhibition of the RAS oncoproteins has proven …

[引用][C] SHP2 is required for growth of KRAS-mutant non-small-cell lung cancer in vivo letter

S Mainardi, A Mulero-Sánchez, A Prahallad… - NATURE …, 2018 - iris.unito.it

SHP2 is required for growth of KRAS-mutant non-small-cell lung cancer in vivo.

S Mainardi, A Mulero-Sánchez, A Prahallad… - Nature …, 2018 - europepmc.org
RAS mutations are frequent in human cancer, especially in pancreatic, colorectal and non-
small-cell lung cancers (NSCLCs) 1-3. Inhibition of the RAS oncoproteins has proven …